Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — J.P. Morgan Healthcare Conference 2014
19 slides from Precigen's conference presentation, Jan 15, 2014
Slide 1: A Better World through Better DNA
A Better World through Better DNA ™ J.P. Morgan Healthcare Conference January 15, 2014
Slide 2: Forward-Looking Statements
Forward-Looking Statements Intrexon Corp. All rights reserved. Intrexon Corporation issharing the following materials for informational purposes only. Such materials do not constitute an offer tosell or thesolicitation of an offer to buy any securities of Intrexon. Any offerandsale of Intrexon’s sec
Slide 3: Intrexon Thesis
Intrexon Thesis We apply engineering principles to biological systems in large and established markets with built-in demand using a scalable capital efficient business model to develop imperative high value applications for present and future generations while delivering meaningful returns to our sh
Slide 4: Artisanal biological systems do not scale
Artisanal biological systems do not scale Industrial leaders in life sciences — the artisanal approach First mover applying engineering principles to biological systems Precise control over function and output of living cells Continuous learning for improved gene programs and cellular systems Produc
Slide 5: Intrexon applies engineering principles to markets
Intrexon applies engineering principles to markets… Integrated technologies that allow us to rapidly design-build-test-learn enable us to predict the probability of success across various applications Health Food Consumer Energy Environment Controlled expression across varying cell types Intrexon Te
Slide 6: With built-in demand
With built-in demand Year World’s Natural Resource Capacity 0.0 0.5 1.0 1.5 2.0 2.5 Built-up land Forest Fishing Key Grazing Carbon Cropland Source: WWF Living Planet Report 2012 A Demand Proxy for Biotechnology
Slide 7: That require new bio-based solutions
That require new bio-based solutions… A new generation of companies led by Intrexon creating A Better World through Better DNA ™ Approaches to developing imperative products with real world value
Slide 8: Using a scalable business model
Using a scalable business model… Exclusive License to Practice All of Intrexon’s technology in a particular Field To commercialize valuable products Backend Economics Cost Recovery Technology Access Fee (Cash/Equity) Alignment of Economic Interests Partner Intrexon Biotools Delivery Model + Biotech
Slide 9: That is capital efficient
That is capital efficient Third Quarter 2013 Third Quarter 2013 Cost Recovery as % of OpEx 28% Deal Money as % of OpEx 32%
Slide 10: Intrexon
INTREXON’
Slide 11: Illustrative applications in Health
Illustrative applications in Health – Gene and cell-based POC/Product Optimization Pre-Clinical Phase I Phase II Phase III Cancers • Melanoma • Breast cancer • Malignant glioma Ocular Diseases • Age-related macular degeneration • Glaucoma Rare Diseases • Friedreich’s ataxia • Mitochondrial disorders
Slide 12: Illustrative applications in Food and Energy
Illustrative applications in Food and Energy • Natural production platforms (plant or microbe) for building block chemicals • Genetically engineered field crops for stress (drought and cold) tolerance • Improved traits for bruise resistance, nutritional benefits, and flavor enhancement in button mus
Slide 13: Illustrative applications in Environment and Consumer
Illustrative applications in Environment and Consumer • Engineering drought tolerant and disease/pest resistant turf grass • Developing new generation of highly-effective, sustainable pest control products • Designing new bio-diverse products for fine and decorative arts, accessories, toys and uniqu
Slide 14: While delivering meaningful returns to shareholders
3 months ended September 30, 2013 9 months ended September 30, 2013 While delivering meaningful returns to shareholders 3 months ended September 30, 2013 9 months ended September 30, 2013 Total Cash and Investments (excluding equity securities) - $309 million Total Equity Securities - $108 million N
Slide 15: Company Focus
Company Focus Increase cost recovery Increase deal money Revenue generation from future royalty streams To Lead the Second Generation of Biotech Increasing revenue streams through Exclusive Channel Collaborations and strategic acquisitions Converting Technology Leadership to Industrial Leadership
Slide 16: Why are we here?
Why are we here? • Establish additional Exclusive Channel Collaborations with companies that are focused, well-managed and with deep expertise in their respective areas • Establish collaborations with technology companies to advance tools and capabilities of synthetic biology • Add excellent talent
Slide 17: Appendix
Appendix Intrexon Corporation and Subsidiaries Reconciliation of GAAP to Non-GAAP Measures (Unaudited) Adjusted EBITDA. To supplement our financial information presented in accordance with U.S. generally accepted accounting principles (“GAAP”), we present Adjusted EBITDA. A reconciliation of Adjuste
Slide 18: Appendix (continued)
Appendix (continued) In addition to the reasons stated above, which are generally applicable to each of the items we exclude from our non-GAAP financial measure, we believe it is appropriate to exclude certain items for the following reasons: Interest expense may be subject to changes in interest ra
Slide 19: Appendix (continued)
Appendix (continued) 1) Pro forma adjusted EBITDA per share, basic and diluted have been calculated for the three and nine month periods ended September 30, 2013 after giving effect to (i) the conversion of 112,906,464 shares of our preferred stock outstanding on January 1, 2013 into 64,517,977 shar